SPM-0606 / Sea Pharmaceuticals - LARVOL DELTA

Sea Pharmaceuticals Announces Strategic Relationship to Advance Treatments For Patients with CNS Disorders (ACCESSWIRE) - "Inotiv Inc will assist Sea to quantify SPM-0404 levels in Clinical Phase 1 and Ph.1b Trials...Sea Pharmaceuticals, LLC...announced its selection of Inotiv Inc...for pre-clinical development IND-enabling studies to support the advancement of Sea's lead molecule SPM-0404 as a potential new oral medicine to treat tinnitus, epilepsy and S-ALS. Sea's SPM-0404 and a second-generation molecule SPM-0606 represent a portfolio strategy of discovery and development of potent, selective, CNS-penetrant molecules targeting excitatory glutamate neurotransmission."

Commercial • Amyotrophic Lateral Sclerosis • Epilepsy